Scientists Decode Cellular RNA Switch That Can Block Dengue Virus Replication

• by Akanksha Mishra
• 2026-10-17 15:24:00

For decades, the arrival of the monsoon season across India and tropical nations has brought an overwhelming wave of dengue infections, filling emergency wards with critical patients suffering from plummeting platelet counts, acute capillary leakage, and life-threatening blood pressure drops. Medical practitioners have long faced a fundamental clinical challenge: despite global scientific advances, there is still no direct antiviral cure or medication specifically designed to eliminate the dengue virus. Patients must rely exclusively on supportive interventions—including paracetamol, intravenous saline drips, glucose infusions, and emergency platelet transfusions. Now, a landmark biomedical discovery by researchers at the All India Institute of Medical Sciences (AIIMS), New Delhi, offers fresh hope. The study reveals that the human body's own cellular machinery contains specific ribonucleic acid (RNA) molecules capable of acting as natural biological switches to suppress viral growth.

Inside the AIIMS Discovery: Dr. Bhupendra Verma's Team Uncovers the Viral Hijacking Mechanism

The study, published on October 14 in the peer-reviewed international scientific journal NAR Molecular Medicine, decodes how the mosquito-borne pathogen manipulates host biology:

Lead Research Team: The investigation was spearheaded by Dr. Bhupendra Verma, Additional Professor in the Department of Biotechnology at AIIMS, New Delhi, working alongside PhD research scholars Diksha Mandhari, Riya Roy, and Akshita Anand.

Why Traditional Antivirals Failed: Once inside the human system, the dengue virus commandeers host cellular machinery, forcing cellular enzymes to churn out millions of viral copies. In severe presentations—such as Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS)—blood plasma leaks into surrounding tissue, causing multi-organ failure. Dr. Verma points out that without direct therapeutic agents designed to shut down this replication process, clinical containment has remained limited to symptom management.

Focus on Transfer RNA Fragments (tRFs): The AIIMS team focused on minute biological fragments generated by the cleavage of transfer RNA (tRNA), known in molecular biology as transfer RNA-derived fragments or "tRFs."

The Dual Switch: How Host Cells Either Fuel or Halt Dengue Multiplication

Utilizing advanced deep RNA sequencing on infected human cell lines, the research team identified critical shifts in host-pathogen interactions:

Altered tRNA Cleavage Patterns: Upon cellular invasion, the dengue virus fundamentally alters the timing, mechanism, and rate at which host cells degrade and process internal tRNA molecules.

Pro-Viral vs Anti-Viral RNA Molecules: Deep sequencing revealed a distinct split among tRFs: while certain RNA fragments inadvertently facilitate the pathogen's lifecycle and boost viral multiplication, other specific tRF molecules act as natural inhibitors that constrain viral expansion.

Hijacking Cellular Signaling Networks: The scientists identified the exact intracellular signaling cascades that the virus hijacks to sustain its virulence. Crucially, the team isolated two distinct RNA molecules that activate this pathway, effectively serving as metabolic accelerators for infection.

Biological Control Levers: In practical terms, human cells contain dual biochemical switches—some capable of amplifying the infection, and others equipped to shut down viral replication completely.

The Path to Targeted Drugs: Moving Beyond Supportive Drips and Transfusions

This molecular blueprint establishes an actionable foundation for next-generation pharmacology:

Identifying the Vulnerable Target: Antiviral drug discovery depends on locating an Achilles' heel in the pathogen's lifecycle. By identifying which tRFs aid the virus and which suppress it, pharmaceutical researchers have a precise molecular target.

Engineered Antiviral Therapeutics: The findings clear the path for small-molecule inhibitors and synthetic oligonucleotide therapies designed to silence pro-viral RNAs while enhancing host molecules that block replication.

Reducing ICU Admissions and Fatalities: By neutralizing the virus's ability to multiply at the early cellular stage, future therapeutics can prevent mild cases from progressing to severe hemorrhagic shock, reducing ICU admissions and lowering mortality rates during annual outbreaks.

Previous Post

Beyond Physical Tiredness: Why Your Brain Feels Drained and How to Recharge

Next Post

Nature's Omega-3 Goldmine: How Daily Fish Oil Boosts Heart, Brain, and Skin Health